A Phase III Study of Multimodality Therapy for Extra-ocular Retinoblastoma

Protocol
08-072
Full Title
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma (COG-ARET 0321)
Phase
III
Purpose

Retinoblastoma is a cancer of the eye. Extra-ocular retinoblastoma is a form of this cancer that has spread outside the eye. Most children with extra-ocular retinoblastoma treated in the past with less intensive therapies did not survive. However, the majority of patients treated at Memorial Sloan-Kettering with stronger therapy (very similar to that being assessed in this protocol) have been cured.

The purpose of this Children’s Oncology Group study is to evaluate the effectiveness of intensive therapy using a variety of treatments in children with previously untreated extra-ocular retinoblastoma. Patients will receive a combination of chemotherapy drugs, and some of them will also receive radiation therapy after chemotherapy is completed. High-dose chemotherapy with stem cell support will be used in patients with more advanced disease.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have a confirmed diagnosis of extra-ocular retinoblastoma.
  • Patients may not have received prior therapy for extra-ocular retinoblastoma.
  • Patients must be age 10 or younger.

For more information and to inquire about eligibility for this study, please contact Dr. Ira Dunkel at 212-639-2153.

Disease(s)
Retinoblastoma
Locations
Related Diseases

Cancer Clinical Trials: Personalizing for Each Patient

Join our experts for a discussion of clinical trials on November 18. Clinical trials can give patients access to new drugs and other treatments before they are widely available, but how do you know if a trial is right for you?

Learn more »